erythrocyte membrane protein band 4.1 like 5Genealiases: BE37 · LULU · LULU1 · YMO1 · YRT
Q-omics provides the consensus-scored EPB41L5 profile across patient tissues and cancer cell-line models. EPB41L5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EPB41L5 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, EPB41L5 protein abundance shows 21,573 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, KICH, and LUAD as cancer lineages where EPB41L5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EPB41L5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EPB41L5 survival associations across molecular data types. EPB41L5 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EPB41L5 RNA expression–survival associations across cancer types. High EPB41L5 expression shows unfavorable associations in BLCA, ACC and UCS, but favorable associations in KIRC, LUAD and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EPB41L5 RNA expression.
This table summarizes EPB41L5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for EPB41L5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EPB41L5 shows lower tumor expression in KICH, KIRC, THCA, LUSC and LUAD and higher tumor expression in STAD. The KICH box plot shows higher EPB41L5 RNA expression in normal versus tumor tissue (log2 FC = −2.188, t-test p < 0.001).
This table shows molecular features associated with EPB41L5 in patient tissues and cancer cell lines. In patient samples, EPB41L5 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, EPB41L5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
